There has been multiple deals recently in the orphan drug space with teva moving on auspex for their neurology assets in huntington's and Tourette's and Hyperion therapeutics bidding for horizon pharma to gain access to their two orphan drug candidates in urea cycles.The biotech companies in the USA have experienced very good appreciation in their share prices ,have plenty of cash looking for a home ,they have been searching worldwide for something to buy.They are now searching in Australia for something to buy as our biotech's are very cheap in comparison especially with the australian dollar so cheap.Neuren is looking very cheap with two orphan drug candidates in Rett syndrome and fragile x in addition to the U.S. army funded trials in Tbi and concussion.Maybe the smart investors have finally realised that neu is a very low risk play and has huge potential going forward.
There has been multiple deals recently in the orphan drug space...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |